NCT07365384

Brief Summary

This randomized controlled clinical trial aims to compare the effects of pelvic-free versus pelvic-restricted robot-assisted gait training (RAGT) on gait pattern, balance, and fear of falling in stroke patients. Stroke survivors often experience gait impairments, reduced balance, and fear of falling, which limit independence and quality of life. Conventional physiotherapy requires high intensity and repetition but is restricted by therapist capacity. Robotic gait systems provide intensive, repetitive, and safe training; however, most limit pelvic motion, potentially disrupting natural gait patterns and balance strategies. A total of 36 participants with chronic stroke (≥6 months post-stroke, age ≥18 years, hemiplegic gait disorder, Functional Ambulation Category ≥2) will be randomized into two groups: (1) pelvic-free RAGT plus conventional rehabilitation, or (2) pelvic-restricted RAGT plus conventional rehabilitation. Interventions will consist of 8 RAGT sessions (twice weekly) and 20 conventional rehabilitation sessions (five times weekly) over 4 weeks. Primary outcomes include gait analysis parameters (gait speed, step length, cadence, temporal symmetry index) and clinical measures such as the Berg Balance Scale, Functional Ambulation Category, Motricity Index (lower limb), and Falls Efficacy Scale-International. Assessments will be performed at baseline and after 4 weeks of treatment. The study hypothesizes that pelvic-free RAGT will improve gait symmetry, balance, and reduce fear of falling more effectively than pelvic-restricted training. Results are expected to provide evidence supporting the integration of pelvic-free robotic gait systems into post-stroke rehabilitation to enhance functional recovery and patient confidence

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
36

participants targeted

Target at P25-P50 for not_applicable stroke

Timeline
Completed

Started Jan 2026

Shorter than P25 for not_applicable stroke

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 26, 2025

Completed
4 months until next milestone

Study Start

First participant enrolled

January 15, 2026

Completed
11 days until next milestone

First Posted

Study publicly available on registry

January 26, 2026

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2026

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2026

Completed
Last Updated

January 26, 2026

Status Verified

January 1, 2026

Enrollment Period

3 months

First QC Date

September 26, 2025

Last Update Submit

January 23, 2026

Conditions

Outcome Measures

Primary Outcomes (6)

  • Berg Balance Scale

    14-item scale assessing static and dynamic balance, scored 0-56 (higher scores indicate better balance).

    Baseline (T0) and 4 weeks post-intervention (T1)

  • Gait Speed

    Gait speed will be assessed using the Zebris FDM-T treadmill system and expressed in meters per second (m/s).

    Baseline (T0) and 4 weeks post-intervention (T1)

  • Step Length

    Step length will be measured with the Zebris FDM-T treadmill system and reported in centimeters (cm).

    Baseline (T0) and 4 weeks post-intervention (T1)

  • Cadence

    Cadence will be recorded using the Zebris FDM-T treadmill system and expressed in steps per minute.

    Baseline (T0) and 4 weeks post-intervention (T1)

  • Double Support Time

    Double support time will be assessed with the Zebris FDM-T treadmill system and expressed as percentage (%) of the gait cycle.

    Baseline (T0) and 4 weeks post-intervention (T1)

  • Temporal Symmetry Index

    Temporal symmetry index will be calculated from gait analysis with the Zebris FDM-T treadmill system and expressed as a percentage (%).

    Baseline (T0) and 4 weeks post-intervention (T1)

Secondary Outcomes (3)

  • Functional Ambulation Category (FAC)

    Baseline (T0) and 4 weeks post-intervention (T1)

  • Motricity Index - Lower Limb

    Baseline (T0) and 4 weeks post-intervention (T1)

  • Falls Efficacy Scale-International (FES-I)

    Baseline (T0) and 4 weeks post-intervention (T1)

Study Arms (2)

Pelvic-Free Robot-Assisted Gait Training + Conventional Rehabilitation

EXPERIMENTAL

Participants will receive 8 sessions of pelvic-free robot-assisted gait training with RoboGait® (2 sessions per week for 4 weeks) in addition to conventional rehabilitation (5 sessions per week for 4 weeks).

Device: RoboGait® Pelvic-Free ModeOther: Conventional Rehabilitation

Pelvic-Restricted Robot-Assisted Gait Training + Conventional Rehabilitation

ACTIVE COMPARATOR

Participants will receive 8 sessions of pelvic-restricted robot-assisted gait training with RoboGait® (2 sessions per week for 4 weeks) in addition to conventional rehabilitation (5 sessions per week for 4 weeks).

Device: RoboGait® Pelvic-Restricted ModeOther: Conventional Rehabilitation

Interventions

Robot-assisted gait training using the RoboGait® system in pelvic-free mode. Participants receive 8 sessions (2 per week for 4 weeks) in addition to conventional rehabilitation.

Pelvic-Free Robot-Assisted Gait Training + Conventional Rehabilitation

Robot-assisted gait training using the RoboGait® system in pelvic-restricted mode. Participants receive 8 sessions (2 per week for 4 weeks) in addition to conventional rehabilitation.

Pelvic-Restricted Robot-Assisted Gait Training + Conventional Rehabilitation

Standard physiotherapy program consisting of 20 sessions (5 per week for 4 weeks) focused on mobility, strengthening, and functional training. Applied to all participants in both groups.

Pelvic-Free Robot-Assisted Gait Training + Conventional RehabilitationPelvic-Restricted Robot-Assisted Gait Training + Conventional Rehabilitation

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age 18 years or older
  • History of stroke more than 6 months prior
  • Presence of hemiplegia-related gait disorder
  • Functional Ambulation Category (FAC) score ≥ 2
  • Ability to walk independently prior to stroke

You may not qualify if:

  • Severe cognitive or communication impairment
  • Movement limitations due to joint contracture or deformity
  • Presence of open wounds or pressure ulcers
  • Uncontrolled hypertension or orthostatic hypotension
  • Severe cardiovascular disease, heart failure, cancer, or serious pulmonary disease
  • High risk of fracture due to severe osteoporosis
  • Gait impairment caused by lower extremity musculoskeletal disorders
  • Severe psychosis/neurosis
  • Modified Ashworth Scale \> 3 in the lower extremities (severe spasticity)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (3)

  • Lee J, Chun MH, Seo YJ, Lee A, Choi J, Son C. Effects of a lower limb rehabilitation robot with various training modes in patients with stroke: A randomized controlled trial. Medicine (Baltimore). 2022 Nov 4;101(44):e31590. doi: 10.1097/MD.0000000000031590.

  • Aurich-Schuler T, Gut A, Labruyere R. The FreeD module for the Lokomat facilitates a physiological movement pattern in healthy people - a proof of concept study. J Neuroeng Rehabil. 2019 Feb 6;16(1):26. doi: 10.1186/s12984-019-0496-x.

  • Alingh JF, Weerdesteyn V, Nienhuis B, van Asseldonk EHF, Geurts ACH, Groen BE. Immediate after-effects of robot-assisted gait with pelvic support or pelvic constraint on overground walking in healthy subjects. J Neuroeng Rehabil. 2019 Mar 15;16(1):40. doi: 10.1186/s12984-019-0506-z.

MeSH Terms

Conditions

StrokeHemiplegiaGait Disorders, Neurologic

Condition Hierarchy (Ancestors)

Cerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesVascular DiseasesCardiovascular DiseasesParalysisNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Central Study Contacts

Meltem Güneş Akıncı, MD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Assistant Professor of Physical Medicine and Rehabilitation, Pamukkale University

Study Record Dates

First Submitted

September 26, 2025

First Posted

January 26, 2026

Study Start

January 15, 2026

Primary Completion

April 1, 2026

Study Completion

April 1, 2026

Last Updated

January 26, 2026

Record last verified: 2026-01

Data Sharing

IPD Sharing
Will not share